Patients must have had HER2 testing performed on the primary breast tumor before neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer; patients who have a primary tumor that is either HER2-positive or HER2-negative are eligible
No prior anti-epidermal growth factor (EGF) or anti-human epidermal growth factor receptor 2 (HER2) therapy
Only for the 1L Cohort: human epidermal growth factor receptor 2 (HER2)-negative tumors;
For Part B exclusively (RO6874281 in combination with trastuzumab), participants with metastatic or recurrent or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer, as defined by the College of American Pathologists HER2 testing guidelines, who have progressed on at least two lines of HER2-directed therapies in the metastatic setting and the last therapy prior to going on study has to contain a HER2-directed antibody; baseline left ventricular ejection fraction (LVEF) of >=50% (measured by echocardiography) predose on Cycle 1 Day 1
Patients who have received prior therapy with any irreversible human epidermal growth factor receptor tyrosine kinase inhibitor
Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, G, and I.
Have a diagnosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer for Parts F and H.
Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy
Part 2, Cohort 5, Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer who have failed prior treatment with a CDK 4/6 inhibitor in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy.
Prior chemotherapy, prior epidermal growth factor receptor (EGFR) targeted therapy, or prior radiation therapy for HNSCC
Patients with metastatic colorectal cancer who have progressed on, or are ineligible for standard therapy such as fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab and anti-epidermal growth factor receptor (EGFR) antibodies where appropriate, but are suitable candidates for regorafenib treatment
No prior epidermal growth factor receptor (EGFR) inhibitor or antiangiogenic agent allowed
Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC
Radiographic documentation of disease progression while on previous continuous treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
For triple-negative breast cancer, a minimum of 1 prior cytotoxic chemotherapy regimen must have been administered for the indication of metastatic disease.Depending on receptor status, 1 or 2 prior cytotoxic regimens are required prior to enrollment in this trial; hormonal and/or human epidermal growth factor receptor 2 (HER2) -targeted agents may be required.
Must have a confirmed Epidermal growth factor receptor amplification in tumor tissue
Patients with recent (within 15 days preoperatively) history deteriorate kidney function (creatinine serum concentrations > 2.5 mg/dL or epidermal growth factor receptor [eGFR] < 30 mL/kg/min)
Histologically or cytologically confirmed solid tumor of one of the following types associated with overexpression of Epidermal Growth Factor Receptor (EGFR) or EGFR ligands: Dose Escalation Phase:
Have documented testing for human epidermal growth factor receptor 2 (HER2-neu) overexpressing, and for those with tumors overexpressing HER2-neu, have documented progression on Trastuzumab-containing therapy
Epidermal growth factor receptor (eGFR) < 50 by Mayo or Cockcroft formula
Patients with known ponatinib-resistant gene alterations\r\n* Platelet derived growth factor receptor, alpha polypeptide (PDGFRA) D842V mutation\r\n* Mast/stem cell growth factor receptor Kit (cKIT) D816V mutation\r\n* FLT3 D835V/Y/H/F or Y842C mutations\r\n* Fibroblast growth factor receptor 3 (FGFR3) K652E mutation
Histologically confirmed diagnosis of advanced (metastatic or unresectable) non-small cell lung cancer (NSCLC) with mutations, rearrangement and fusion involving RET oncogene, or abnormalities in the pazopanib target genes defined as vascular endothelial growth factor receptors 1-3 (VEGFR1-3), platelet-derived growth factor receptor-alpha (PDGFRA), or platelet-derived growth factor receptor-beta (PDGFRB), or tumor protein p53 (TP53) with abnormalities including deletion, insertion, early stop codon, and/or nonsynonymous mutations with functional consequences; Clinical Laboratory Improvement Act (CLIA) certified lab testing for pazopanib target genes using cell free deoxyribonucleic acid (DNA) from peripheral blood and/or assays performed on tumor tissues are acceptable
COHORT II: Core tissue must have human epidermal growth factor receptor 2 (HER 2) testing
Human epidermal growth factor receptor 2 (HER2)-neu positive
Have either human epidermal growth factor receptor 2 positive (HER2+) (Study Part A) or HER2- (Study Part B) breast cancer.
Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor receptor inhibitor within at least 4 weeks of the date of first administration of study drug
Tumors must demonstrate epidermal growth factor receptor (EGFR) amplification.
Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis
Prior treatment with tyrosine-kinase inhibitors targeting VEGF, platelet-derived growth factor, fibroblast growth factor, tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (TIE-2), or angiopoietin (or their receptors)
Patients who are found to have a cancer positive for the marker human epidermal growth factor receptor 2 (HER-2)/neu (Note: this exclusion criterion applies only to patients at the New York University [NYU] Tisch and Bellevue sites where there is currently a protocol open and available for patients who are HER-2/neu positive; this exclusion criterion does not apply to patients at the South Africa site)
Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer or ovarian cancer should have received at least two lines of systemic therapy in the advanced setting
Patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule)
Prior therapy with any agent targeting the HER2 pathway or human epidermal growth factor receptor 1 (HER1) (epidermal growth factor receptor [EGFR]) pathway
Prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway
Patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule)
Patients who have received prior therapy with trastuzumab or any other anti-epidermal growth factor type II receptor antibody
Plan to administer any other systemic antitumor including endocrine therapy except for following standard of care treatment:\r\n* Trastuzumab at standard dosing human epidermal growth factor receptor 2 (HER2) positive tumors\r\n* Denosumab or bisphosphonates to treat metastatic bone disease
Tumor shown to be human epidermal growth factor 2 plus (HER2+)
Prior treatment with anti-epidermal growth factor receptor (EGFR) therapy (either panitumumab or cetuximab)
Absence of known epidermal growth factor receptor (EGFR) mutation
Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)
Human Epidermal Growth Factor Receptor 2 (HER2)-positive gastric cancer
have received prior second-line treatment with oxaliplatin and/or irinotecan, and no other licensed/standard-of-care therapies are available. If the participant has RAS wild type colorectal cancer, he or she also must have received prior treatment with an epidermal growth factor receptor monoclonal antibody
Patients with the factor interacting with poly(A) polymerase alpha (PAPOLA) and cleavage and polyadenylation specific factor 1 (CPSF1) (FIP1L1)-platelet-derived growth factor receptor, alpha polypeptide (PDGFRalpha) fusion even with resistance to imatinib (such patients are no longer defined as systemic mastocytosis by the WHO)
Participants with human epidermal growth factor receptor 2 (HER2)-positive status.
Have a diagnosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Prior therapy with agents targeting Insulin Growth Factor (IGF) and/or Insulin Growth Factor Receptor (IGFR) pathway.
Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions =< 2 cm) that are estrogen or progesterone receptor positive and do not exhibit human epidermal growth factor receptor 2 (HER2)/neu gene amplification OR ductal carcinoma in situ (lesions =< 2 cm)
Pathologic (histologically or cytologically) documented extracranial diagnosis of primary lung cancer, melanoma, human epidermal growth factor receptor 2 (HER2)-amplified or immuno-positive breast cancer, or HER2-amplified or immuno-positive gastric cancer, with brain metastasis detected by contrast enhanced magnetic resonance imaging (MRI) or computed tomography (CT) is required; patients with concurrent leptomeningeal diseases are eligible
Human epidermal growth factor receptor 2 (HER-2) status may be pending at initiation of FOLFIRINOX, but must be known prior to starting trastuzumab; if HER-2 is positive, patients must have a left ventricular ejection fraction (LVEF) >= 50%; HER-2 negative patients are not excluded
Documentation of human epidermal growth factor receptor 2 (HER2)-negative tumor.
The patient must have a pathologically confirmed (by histology, cytology, or immunohistology) diagnosis of TNBC (a cancer that does not meaningfully express the estrogen or progesterone hormone receptors or overexpress the human epidermal growth factor receptor 2 tyrosine kinase), which is currently advanced/metastatic disease.
Human epidermal growth factor receptor 2 (HER-2) positive esophagogastric cancer; patients with unknown HER2 status are permitted
Known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy
Participants must have histologically confirmed hormone receptor positive (HR+), human epidermal growth factor 2 (HER2) negative stage II or stage III invasive breast cancer; evaluation for metastatic disease is not required in the absence of symptoms
If Human Epidermal Growth Factor Receptor (HER2) positive, subjects must have received and progressed on at least one prior standard HER2 directed therapy or the subject must be ineligible to receive anti-HER2 therapy.
Prior treatment with an investigational or marketed inhibitor of the epidermal growth factor receptor (EGFR) pathway or an Aurora Kinase inhibitor
Patients with mutations in the epidermal growth factor receptor (EGFR) gene; the mutational status of all patients with adenocarcinoma and non-squamous histology will be determined prior to study entry
Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.
Prior treatment with epidermal growth factor receptor targeting small molecules or antibodies.
Prior anti-epidermal growth factor receptor antibody therapy (e.g. panitumumab or cetuximab) or prior small molecule anti-epidermal growth factor receptor therapy (e.g. erlotinib) for adenocarcinoma of the small bowel or ampulla of Vater
Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent.
Prior treatment with a PI3K/mTOR inhibitor, epidermal growth factor receptor (EGFR) inhibitor, and/or necitumumab.
Subjects that are known to be epidermal growth factor (EGFR)-activating mutation positive must have received an EGFR inhibitor.
Tumor tissue available for epidermal growth factor receptor (EGFR) expression analysis
Prior treatment with tyrosine-kinase inhibitors targeting VEGF, platelet-derived growth factor, fibroblast growth factor, tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (TIE-2), or angiopoietin (or their receptors)
Epidermal growth factor receptor (EGFR) mutations
Human epidermal growth factor receptor 2 (HER2)/neu negative on the core biopsy analysis defined as 0 or 1+ by immunohistochemistry or not amplified by fluorescent in situ hybridization analysis
Prior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules, EGFR-targeted antibodies, and/or any investigational agents for HNSCC
Human epidermal growth factor receptor 2 (HER2) normal (immunohistochemistry [ICH] 0-1; fluorescence in situ hybridization [FISH] < 2.0)
Adequate tissue for central immunohistochemical (IHC) assay of Met receptor, and epidermal growth factor receptor (EGFR) testing if EGFR status is unknown
There should be a minimum of 4 weeks from any prior chemotherapy, immunotherapy and/or radiation, with the exception of hormonal therapy for prostate and breast cancers, human epidermal growth factor receptor (HER)2-directed therapy for HER2+ breast cancer (3+ immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH]+), and erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancer in the expansion cohort; there should be a minimum of 6 weeks from any prior antibody therapies, (such as ipilimumab or anti-programmed cell death [PD]1/programmed death-ligand [PDL]1)
Prior therapy targeting the epidermal growth factor receptor (EGFR) pathway
Unknown epidermal growth factor receptor (EGFR)mutation status or previously known EGFR mutated status in patients with adenocarcinoma.
Prior treatment with an investigational or approved agent for the purpose of inhibiting human epidermal growth factor receptor (HER) family members. This includes, but is not limited to, cetuximab, panitumumab, erlotinib, gefitinib, and lapatinib
Prior treatment with an epidermal growth factor receptor (EGFR) inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed/terminated >/= 3 months before study enrollment
Patients who received prior phosphoinositide-3-kinase (PI3K) inhibitor or anti-receptor tyrosine-protein kinase erbB-3 (ERBB3 or HER3) antibody treatment, including bi-specific antibodies with HER3 as one of the targets (patients with prior exposure to pertuzumab or epidermal growth factor receptor (EGFR)-targeted agents are eligible)
Patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer are also excluded from this portion of the study
Subjects must have a solid tumor type likely to over-express Epidermal Growth Factor Receptor (EGFR) (Phase 1)
Prior treatment with investigational drugs that target the human growth factor (HGF) or MET pathway
Prior treatment with any anti-HER3 (Human Epidermal growth factor Receptor 3) treatment
Results of endothelial growth factor receptor (EGFR)-activating mutation testing
Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing
Prior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules
The participant has a history of treatment with other agents targeting the Insulin-like or Epidermal Growth factor receptors.
Human epidermal growth factor receptor 2 (HER-2)/neu negative (phase II)
Paraffin-embedded tumor tissue from primary tumor or metastasis for determination of epidermal growth factor receptor expression and biomarker testing
Prior use of any monoclonal antibodies directly targeting the epidermal growth factor receptor (EGFr). Subjects who have received prior tyrosine kinase inhibitors such as gefitinib or erlotinib are eligible.
Treatment plan that includes any neoadjuvant or adjuvant therapy (either in the context of standard treatment or a clinical trial and including chemotherapy, treatments targeting the human epidermal growth factor receptor protein 2 [HER2]), hormonal therapy, or radiation; patients can receive any/all of these therapy components while on study in any combination
Completed adjuvant taxane-based chemotherapy as single agents or in combination with platins or human epidermal growth factor receptor 2 (HER-2) directed therapy
Patients must have a diagnosis of colorectal or lung cancer and be planning to receive one of the following human epidermal growth factor receptor (HER1)/epidermal growth factor receptor (EGFR) inhibitor therapies listed below for at least 6 weeks:\r\n* Cetuximab 400 mg/m^2 loading dose, 250 mg/m^2 weekly\r\n* Cetuximab 500 mg/m^2 every 2 weeks\r\n* Panitumumab 6 mg/kg every 2 weeks\r\n* Erlotinib 100-150 mg daily\r\n* Other HER1/EGFR inhibitor therapies, schedules, or doses of the above listed agents are not allowed\r\n* NOTE: concurrent chemotherapy and other anti-cancer therapies (such as carboplatin, paclitaxel, and bevacizumab) are allowed EXCEPT for the following chemotherapeutic agents which are known to cause skin rash that could interfere with EGFRI-induced skin toxicity assessment: gemcitabine, capecitabine, and topical fluorouracil (Efudex, Fluoroplex, Carac)
Subject is currently on anti-EGFR (human epidermal growth factor receptor) therapy, such as Iressa (gefitinib) or Erbitux (cetuximab, C225)
Have histologic diagnosis of human epidermal growth factor receptor 2 (HER2) positive (+) breast carcinoma
Histological or cytological confirmation of hormone-receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer
Patients must have had HER2 testing performed on the primary breast tumor collected prior to neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer; patients who have a primary tumor that is HER2-positive, HER2-equivocal, or HER2-negative are eligible
Patient must NOT have human epidermal growth factor-2 positive (HER2+) metastatic disease
Impaired renal function defined as epidermal growth factor receptor (eGFR) < 50 mL/min/1.73m2
Patients with human epidermal growth factor-2 positive (HER2+) metastatic tumors are NOT eligible.
Patient must NOT be planning to receive everolimus nor human epidermal growth factor receptor 2 (HER2) directed therapy in addition to endocrine therapy.
Participants must have histologically or cytologically confirmed human epidermal growth factor receptor 2 (HER2) negative invasive breast adenocarcinoma
Histologic diagnosis of triple negative or human epidermal growth factor receptor 2 (HER2) amplified breast cancer, clinical stage T1-4, N0-3, M0/1 receiving preoperative systemic therapy and planned surgery